Stock LUNG PULMONX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pulmonx Corporation

Equities

LUNG

US7458481014

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
7.28 USD -0.27% Intraday chart for Pulmonx Corporation -3.06% -42.90%
04-02 Pulmonx Appoints Mehul Joshi as Chief Financial Officer MT
04-02 Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
PULMONX CORPORATION Stock Pulmonx Corporation
-42.90% 283M
C-
SHOCKWAVE MEDICAL, INC. Stock Shockwave Medical, Inc.
+73.17% 12.38B
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-18.74% 7.92B
C+
MASIMO CORPORATION Stock Masimo Corporation
+16.15% 7.2B
C-
GETINGE AB Stock Getinge AB
+4.81% 5.84B
B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+5.99% 5.07B
D+
APT MEDICAL INC. Stock APT Medical Inc.
+27.07% 4.53B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-21.67% 3.88B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-40.82% 2.23B
C
SKAN GROUP AG Stock SKAN Group AG
+1.49% 2.02B -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LUNG Stock
  4. Ratings Pulmonx Corporation